Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences

Mansing Ratanasukon, Patama Bhurayanontachai, Pichai Jirarattanasopa Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla Province 90110, ThailandPurpose: The purpose of this article was to study the real-life treatment results of polypoidal choroidal vas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	polypoidal choroidal vasculopathy anti-vascular endothelial growth factor photodynamic therapy Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/b62d06498d9545b9baa8c39386ee94bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b62d06498d9545b9baa8c39386ee94bb
record_format	dspace
spelling	oai:doaj.org-article:b62d06498d9545b9baa8c39386ee94bb2021-12-02T00:07:49ZPolypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences1177-5483https://doaj.org/article/b62d06498d9545b9baa8c39386ee94bb2018-10-01T00:00:00Zhttps://www.dovepress.com/polypoidal-choroidal-vasculopathy-pcv-the-4-year-review-of-the-real-li-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Mansing Ratanasukon, Patama Bhurayanontachai, Pichai Jirarattanasopa Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla Province 90110, ThailandPurpose: The purpose of this article was to study the real-life treatment results of polypoidal choroidal vasculopathy (PCV).Design: This was a retrospective study.Methods: Patients with presumed age-related macular degeneration were reviewed, and PCV diagnosis was made using the EVEREST study criteria. Outcomes were changes in visual acuity (VA) and central retinal thickness, time between treatments, follow-up time, and number of treatments.Results: The prevalence of PCV was 30.8%. At the beginning, 195 eyes received monotherapy of anti-vascular endothelial growth factor (anti-VEGF) injections, either bevacizumab or ranibizumab, and only six eyes received the combination of anti-VEGF injection and photodynamic therapy (PDT) at the time of the first treatment. During the follow-up, some patients received “rescue or add-on” PDT when they had a poor response after anti-VEGF injections. After 4 years, the average number of injections was 8.25 and 9.15 for the anti-VEGF monotherapy and the combination groups, respectively. The average time between the first anti-VEGF injections and the first PDT was 21.4 months. The average VA in the anti-VEGF monotherapy group increased by 1.5 letters, whereas it decreased by 0.95 letters in the combination group (P=0.48).Conclusion: The review demonstrated the same visual outcomes between the combination therapy of anti-VEGF injections and rescue or add-on PDT vs monotherapy anti-VEGF injections in PCV treatment. When compared with EVEREST II and Planet studies, the “initial” or “rescue or add-on PDT” might have different effects on the final visual outcomes.Keywords: polypoidal choroidal vasculopathy, anti-vascular endothelial growth factor, photodynamic therapyRatanasukon MBhurayanontachai PJirarattanasopa PDove Medical Pressarticlepolypoidal choroidal vasculopathyanti-vascular endothelial growth factorphotodynamic therapyOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 2177-2181 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	polypoidal choroidal vasculopathy anti-vascular endothelial growth factor photodynamic therapy Ophthalmology RE1-994
spellingShingle	polypoidal choroidal vasculopathy anti-vascular endothelial growth factor photodynamic therapy Ophthalmology RE1-994 Ratanasukon M Bhurayanontachai P Jirarattanasopa P Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
description	Mansing Ratanasukon, Patama Bhurayanontachai, Pichai Jirarattanasopa Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla Province 90110, ThailandPurpose: The purpose of this article was to study the real-life treatment results of polypoidal choroidal vasculopathy (PCV).Design: This was a retrospective study.Methods: Patients with presumed age-related macular degeneration were reviewed, and PCV diagnosis was made using the EVEREST study criteria. Outcomes were changes in visual acuity (VA) and central retinal thickness, time between treatments, follow-up time, and number of treatments.Results: The prevalence of PCV was 30.8%. At the beginning, 195 eyes received monotherapy of anti-vascular endothelial growth factor (anti-VEGF) injections, either bevacizumab or ranibizumab, and only six eyes received the combination of anti-VEGF injection and photodynamic therapy (PDT) at the time of the first treatment. During the follow-up, some patients received “rescue or add-on” PDT when they had a poor response after anti-VEGF injections. After 4 years, the average number of injections was 8.25 and 9.15 for the anti-VEGF monotherapy and the combination groups, respectively. The average time between the first anti-VEGF injections and the first PDT was 21.4 months. The average VA in the anti-VEGF monotherapy group increased by 1.5 letters, whereas it decreased by 0.95 letters in the combination group (P=0.48).Conclusion: The review demonstrated the same visual outcomes between the combination therapy of anti-VEGF injections and rescue or add-on PDT vs monotherapy anti-VEGF injections in PCV treatment. When compared with EVEREST II and Planet studies, the “initial” or “rescue or add-on PDT” might have different effects on the final visual outcomes.Keywords: polypoidal choroidal vasculopathy, anti-vascular endothelial growth factor, photodynamic therapy
format	article
author	Ratanasukon M Bhurayanontachai P Jirarattanasopa P
author_facet	Ratanasukon M Bhurayanontachai P Jirarattanasopa P
author_sort	Ratanasukon M
title	Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
title_short	Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
title_full	Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
title_fullStr	Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
title_full_unstemmed	Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
title_sort	polypoidal choroidal vasculopathy (pcv): the 4-year review of the real-life treatment experiences
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b62d06498d9545b9baa8c39386ee94bb
work_keys_str_mv	AT ratanasukonm polypoidalchoroidalvasculopathypcvthe4yearreviewofthereallifetreatmentexperiences AT bhurayanontachaip polypoidalchoroidalvasculopathypcvthe4yearreviewofthereallifetreatmentexperiences AT jirarattanasopap polypoidalchoroidalvasculopathypcvthe4yearreviewofthereallifetreatmentexperiences
_version_	1718403949812252672

Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences

Ejemplares similares